Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20,729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Small Molecule and Pooled CRISPR Screens Investigating IL17 Signaling Identify BRD2 as a Novel Contributor to Keratinocyte Inflammatory Responses.
Slivka PF, Hsieh CL, Lipovsky A, Pratt SD, Locklear J, Namovic MT, McDonald HA, Wetter J, Edelmayer R, Hu M, Murphy E, Domanus M, Lu C, Duggan R, King J, Scott VE, Donnelly-Roberts D, Slavin A, Gopalakrishnan S, Chung N, Goedken ER. Slivka PF, et al. Among authors: lu c. ACS Chem Biol. 2019 May 17;14(5):857-872. doi: 10.1021/acschembio.8b00260. Epub 2019 Apr 15. ACS Chem Biol. 2019. PMID: 30938974
Building a translational cancer dependency map for The Cancer Genome Atlas.
Shi X, Gekas C, Verduzco D, Petiwala S, Jeffries C, Lu C, Murphy E, Anton T, Vo AH, Xiao Z, Narayanan P, Sun BC, D'Souza AL, Barnes JM, Roy S, Ramathal C, Flister MJ, Dezso Z. Shi X, et al. Among authors: lu c. Nat Cancer. 2024 Aug;5(8):1176-1194. doi: 10.1038/s43018-024-00789-y. Epub 2024 Jul 15. Nat Cancer. 2024. PMID: 39009815 Free PMC article.
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: lu c. Signal Transduct Target Ther. 2022 Feb 21;7(1):51. doi: 10.1038/s41392-021-00870-3. Signal Transduct Target Ther. 2022. PMID: 35185150 Free PMC article.
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R, Dunbar F, Lu C, Robinson K, Quarless D, Warder SE, Mukherjee N, Pesko J, Souers AJ, Waring JF, Davids MS, Tausch E, Stilgenbauer S, Ross JA, Leverson JD, Kim SY, Chyla BJ. Popovic R, et al. Among authors: lu c. Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24. Am J Hematol. 2022. PMID: 34779028 Free PMC article. No abstract available.
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K Jr, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Zhang Q, et al. Among authors: lu c. Signal Transduct Target Ther. 2022 Apr 1;7(1):110. doi: 10.1038/s41392-022-00958-4. Signal Transduct Target Ther. 2022. PMID: 35365596 Free PMC article. No abstract available.
20,729 results
You have reached the last available page of results. Please see the User Guide for more information.